<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9504">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744497</url>
  </required_header>
  <id_info>
    <org_study_id>CA180-227</org_study_id>
    <secondary_id>2008-000701-11</secondary_id>
    <nct_id>NCT00744497</nct_id>
  </id_info>
  <brief_title>Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer</brief_title>
  <acronym>READY</acronym>
  <official_title>A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>India: Drugs Controller General of India</authority>
    <authority>Ireland: Irish Medicines Board</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <authority>Norway:National Committee for Medical and Health Research Ethics</authority>
    <authority>Peru: Health National Institute</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Russia: FSI Scientific Center of Expertise of Medical Application</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether survival can be prolonged in patients with
      castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival: Time From Randomization to Date of Death</measure>
    <time_frame>From randomization to death or date of last contact (maximum reached: 45 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival is defined as time in months from the randomization date to the date of death due to any cause (in the randomized population). If the patient did not die, survival was censored on the last date he or she was known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Objective Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>At baseline and every 12 weeks thereafter to end of treatment, at end of treatment, and at follow-up (within 42 days of end of dosing)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective tumor response rate=the percentage of randomized participants with a best tumor response of partial (PR) or complete response (CR), within 42 days of end of dosing, divided by total number of patients who were evaluable (with at least 1 target lesion at baseline). By RECIST: CR=disappearance of clinical and radiologic evidence of target and nontarget lesions confirmed by another evaluation at least 6 weeks later. PR=a &gt;30% or greater decrease in the sum of longest diameter (LD) of target lesions in reference to the baseline sum LD confirmed by another evaluation at least 6 weeks later. Stable disease=neither sufficient increase to qualify for PD nor shrinkage to qualify for PR, and at least 8 weeks since start of study therapy. Progressive disease=a 20% or greater increase in sum of LD of all target lesions, taking as reference the smallest sum of LD at or following baseline, or unequivocal progression on existing nontarget lesions, or new lesions are present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Skeletal-related Event (SRE)</measure>
    <time_frame>From day of randomization to date of first SRE or to last SRE assessment, if subsequent cancer therapy begun or no SRE (maximum reached: 42 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to first SRE is defined as the time in months from the date of randomization to the date of first SRE (unless SRE occurred while the patient was undergoing subsequent cancer therapy). Participants with a first SRE while on subsequent cancer therapy, those who died without a reported SRE, and those who did not have an SRE were censored on the date of their last SRE assessment prior to start of subsequent cancer therapy, if any. Participants who had no SRE assessments were censored on the day they were randomized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With A Reduction in Urinary N-telopeptide (uNTx) Level From Baseline</measure>
    <time_frame>At baseline, prior to each docetaxel infusion (every 3 weeks) to end of treatment, at end of treatment, and at follow-up (within 14 days of end of dosing)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants who had an on-study uNTx value confirmed (at least 3 weeks later) within normal limits (or ≥3 and &lt;60 nmol/mmol creatinine, if normal limits were missing) or an on-study uNTx level reduction from baseline of ≥35%, even when on-study uNTx value remained abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From day of randomization to disease progression or death (or to last clinical assessment, if subsequent cancer therapy started or no progression or death) (maximum reached: approximately 43 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Those who progressed or died while on subsequent cancer therapy and those who did not die or progress were censored at their last radiologic bone scan/imaging, skeletal related-event, or tumor assessment or at measurement of prostate specific antigen levels, whichever occurred last prior to start of subsequent cancer therapy ,if any. Participants with no assessments were censored on the day of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Prostate Specific Antigen (PSA) Progression</measure>
    <time_frame>From randomization to date of first PSA measurement leading to confirmed PSA progression (or to last bone scan assessment, if no progression or if cancer therapy started) (maximum reached: 30 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>PSA progression is defined as the time from randomization to the date of the first PSA level measurement that led to confirmed PSA progression, for participants who had not started subsequent cancer therapy. For participants who did not progress or who progressed on cancer therapy, PSA progression is defined as the time from randomization to the date of the last PSA level measurement before the start of cancer therapy, if any. Participants who had no on-study PSA level measurements were censored on the day they were randomized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Reduction in Pain Intensity From Baseline</measure>
    <time_frame>At baseline, prior to each docetaxel infusion (every 3 weeks), at end of treatment, and at follow-up (within 14 days of end of dosing)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants with a reduction in pain intensity from baseline was defined as the number of participants who achieved a 30% or more decrease in pain intensity from baseline for at least 2 consecutive pain assessments (at least 14 days apart) within 14 days of end of dosing divided by the number of randomized participants who had a baseline pain intensity of at least 2. Pain intensity was assessed based on question 3 of the brief pain inventory questionnaire.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation</measure>
    <time_frame>Continuously throughout study to &gt;=30 days after last dose of study drug until resolution of drug-related toxicity, or when toxicity was deemed irreversible, whichever shorter.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=having certain, probable, possible, or missing relationship to study drug</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Adverse Events (AEs) of Special Interest</measure>
    <time_frame>Continuously throughout study to &gt;=30 days after last dose of study drug until resolution of drug-related toxicity, or when toxicity was deemed irreversible, whichever was shorter</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. AEs of Special Interest=recognized events in other agents within this drug class or events for which safety data from nonclinical and clinical studies with dasatinib indicate that careful evaluation is warranted. AEs of Special Interest are identified by the medical and safety representatives of the sponsor based on MedDRA preferred terms or laboratory data. ANC=absolute neutrophil count.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Abnormalities in Results of Clinical Laboratory Tests in Hematology</measure>
    <time_frame>At baseline, within 3 days prior to each infusion of docetaxel (each cycle) and at end of treatment. If docetaxel is discontinued, every other cycle.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Abnormalities were graded according to the Common Toxicity Criteria (CTC), version 3.0, of the National Cancer Institute. CTC are graded from 1 (least severe) to 4 (life threatening ). Grade 3 and 4 criteria are defined as follows: Absolute neutrophil count, Grade 3, neutrophils &lt;1.0-0.5*10^9/L; Grade 4, &lt;0.5*10^9/L. Hemoglobin, Grade 3, &lt;4.9-4.0 mmol/L; Grade 4, &lt;4.0 mmol/L. Platelets, Grade 3, &lt;50.0-25.0*10^9/L; Grade 4, &lt;25.0*10^9/L. Leukocytes, Grade 3, &lt;2.0-1.0*10^9/L; Grade 4, &lt;1.0*10^9/L.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Abnormalities in Results of Clinical Laboratory Tests Assessing Liver Function, Renal Function, and Electrolytes</measure>
    <time_frame>At baseline, within 3 days prior to each infusion of docetaxel (each cycle), to end of treatment. If docetaxel is discontinued, every other cycle.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal. Abnormalities were graded according to the Common Toxicity Criteria (CTC), version 3.0, of the National Cancer Institute. CTC are graded from 1 (least severe) to 4 (life threatening). ALP, ALT, and AST, Grade 3, &gt;5.0-20.0*ULN; Grade 4, &gt;20.0*ULN. Total bilirubin, Grade 3, &gt;3.0-10.0*ULN; Grade 4, &gt;10.0*ULN. Creatinine, Grade 3, &gt;3.0-6.0*ULN; Grade 4, &gt;6.0*ULN. Hypercalcemia(serum calcium, mmol/L), Grade 3, &gt;3.1-3.4; Grade 4, &gt;3.4. Hypocalcemia (serum calcium, mmol/L), Grade 3, &lt;1.75-1.5; Grade 4, &lt;1.5. Hyperkalemia(serum calcium, mmol/L), Grade 3, &gt;6.0-7.0; Grade 4, &gt;7.0. Hypokalemia(serum calcium, mmol/L), Grade 3, &lt;3.0-2.5; Grade 4, &lt;2.5. Hypernatremia (serum calcium, mmol/L), Grade 3, &gt;155-160; Grade 4, &gt;160. Hyponatremia (serum sodium, mmol/L), Grade 3, &lt;130-120; Grade 4, &lt;120. Phosphorus (serum sodium, mmol/L), Grade 3, &lt;0.6-0.3; Grade 4, &lt;0.3.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Abnormal Results in Urinalysis</measure>
    <time_frame>At baseline, within 3 days prior to each infusion of docetaxel (each cycle), to end of treatment. If docetaxel is discontinued, every other cycle.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Abnormal=positive, defined as the presence of &gt;=30 mg/dL of protein; a small, moderate, or large amount of blood; or &gt;0 g/dL glucose in urine. BL=baseline; neg=negative</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants by Maximal On-study Fridericia-corrected QTc Interval by Electrocardiogram</measure>
    <time_frame>At baseline, approximately 12 weeks after starting treatment, and then whenever clinically indicated up to within 30 days of end of dosing</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Changes From Baseline in Fridericia-corrected QTc Interval by Electrocardiogram</measure>
    <time_frame>At baseline, approximately 12 weeks after starting treatment, and then whenever clinically indicated up to within 30 days of end of dosing</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With and Without Pericardial Effusion at Baseline and On-study and With Left Ventricular Ejection Fraction (LVEF) &lt;40% and &gt;=40%On-study by Echocardiogram</measure>
    <time_frame>At baseline, approximately 12 weeks after start of treatment, and thereafter whenever clinically indicated</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>BL=baseline; OS=on-study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1930</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <arm_group_label>Dasatinib</arm_group_label>
    <other_name>Sprycel</other_name>
    <other_name>BMS-354825</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Dasatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Dasatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of histologically diagnosed prostate cancer

          -  Evidence of metastatic disease by any 1 of the following: computed tomography scan,
             magnetic resonance imaging, bone scan, or skeletal survey

          -  Evidence of progression, as defined by 1 of the following: rising prostate specific
             antigen levels at least 1 week apart with the final value being &gt;=2 ng/mL;
             progression of measurable nodal or visceral disease, with nodal lesions &gt;=20 mm and
             visceral lesions measurable per response evaluation criteria for solid tumors
             (Response Evaluation in Solid Tumors, version 1); 2 or more lesions appearing on bone
             scan compared with previous scan; or local recurrence in the prostate or prostate bed

          -  Maintaining castrate status: Participants who have not undergone surgical orchiectomy
             should have received and continue on medical therapies, such as gonadotropin
             releasing hormone analogs, to maintain castrate levels of serum testosterone &lt;=50
             ng/dL

          -  Eastern Cooperative Oncology Group Performance Status of 0 to 2

          -  At least 4 weeks since an investigational agent prior to starting study therapy

          -  At least 8 weeks since radioisotope therapy prior to starting study therapy

          -  Recovery from any local therapy including surgery or radiation/radiotherapy for a
             minimum of 7 days prior to starting study therapy

          -  Required initial laboratory values: white blood cell count &gt;=3,000/mm^3; absolute
             neutrophil count &gt;=1,500/mm^3; platelet count &gt;=100,000/mm^3; creatinine level
             &lt;=1.5*upper limit of normal (ULN); bilirubin &lt;=ULN; aspartate aminotransferase
             &lt;=2.5*ULN; alanine aminotransferase &lt;=2.5*ULN.

        Exclusion Criteria:

          -  Symptomatic brain metastases or leptomeningeal metastases

          -  Clinically significant cardiovascular disease, including myocardial infarction;
             ventricular tachyarrhythmia within 6 months; prolonged QTc &gt;450 msec; ejection
             fraction &lt;40%; or major conduction abnormality, unless a cardiac pacemaker is present

          -  Pleural or pericardial effusion of any Common Terminology Criteria (CTC) grade

          -  Peripheral neuropathy CTC Grade &gt;=2

          -  Currently active second malignancy other than nonmelanoma skin cancers. Participants
             are not considered to have a currently active malignancy if they have completed
             therapy and are now considered (by their physician) to be at less than 30% risk for
             relapse

          -  Uncontrolled intercurrent illness including ongoing or active infection, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  HIV infection-positive patients receiving combination antiretroviral therapy

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to the investigational agents

          -  Receipt of any other investigational agents for the treatment of prostate cancer

          -  Prior cytotoxic chemotherapy in the metastatic setting, with the exception of
             estramustine

          -  Patients may continue on a daily multivitamin but must discontinue all other herbal,
             alternative, and food supplements before enrollment

          -  Ketoconazole must be discontinued 4 weeks prior to starting study therapy

          -  Antiandrogens must be discontinued prior to starting study therapy. Patients with a
             history of response to an antiandrogen and subsequent progression while on that
             antiandrogen should be assessed for antiandrogen withdrawal response for 4 weeks.
             Observation for antiandrogen withdrawal response is not necessary for those who have
             never responded to antiandrogens

          -  Bisphosphonates must not be initiated within 28 days prior to starting study therapy

          -  QT prolonging agents strongly associated with torsade de pointes.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of South Alabama / Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alaska Clinical Research Center, Llc</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group, Inc.</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Hematology Oncology Medical Group</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group Inc</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Clinical Oncology Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Va San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Alexson, Md, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Oncology Group</name>
      <address>
        <city>Middletown</city>
        <state>Connecticut</state>
        <zip>06457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Va Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Hospital System Inc.</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwestern Regional Medical Center</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology And Hematology Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center Of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Center For Cancer Medicine</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Oncology Associates, Pllc</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Hematology And Oncology Associates, Ltd</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, Pc</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, Pc</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samuel S. Stratton Vamc</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hematology Oncology Associates, Pllc</name>
      <address>
        <city>Winston-salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Health System</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Ohio Oncology/Hematology, Inc,Dba</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Med Ctr</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hemetology Oncology, Pc</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upmc Cancer Pavilion</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Va Pittsburgh Healthcare System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates In Hematology &amp; Oncology, P.C.</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers Of The Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Baskin Cancer Foundation</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists Of South Texas, Pa</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Texas Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Regional Cancer System</name>
      <address>
        <city>Lacey</city>
        <state>Washington</state>
        <zip>98503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean Hematology And Oncology Clinic</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1417</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>C1405BCJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ramos Mejia</city>
        <state>Buenos Aires</state>
        <zip>1234</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cipolletti</city>
        <state>Rio Negro</state>
        <zip>R8324BEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000CVD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DSK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Miguel De Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000IAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordaba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Douglas</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <zip>4164</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ringwood</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6162</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41950</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barretos</city>
        <state>Sao Paulo</state>
        <zip>14784</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13083</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jau</city>
        <state>Sao Paulo</state>
        <zip>17210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santo Andre</city>
        <state>Sao Paulo</state>
        <zip>09060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20230</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>22551</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Abbottsford</city>
        <state>British Columbia</state>
        <zip>V2S 3N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Owen Sound</city>
        <state>Ontario</state>
        <zip>N4K 2J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1Y5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 5T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vaasa</city>
        <zip>65130</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St Genis Laval</city>
        <zip>69230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Strasbourg</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kirchheim</city>
        <zip>73230</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Markkleeberg</city>
        <zip>04416</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jaipur</city>
        <zip>302013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kolkata</city>
        <zip>700 053</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kolkatta</city>
        <zip>700 016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin 7</city>
        <state>Dublin</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tallaght</city>
        <state>Dublin</state>
        <zip>DUBLIN 24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <zip>22010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Df</city>
        <state>Distrito Federal</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico D.f.</city>
        <state>Distrito Federal</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tlalpan</city>
        <state>Distrito Federal</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tlalpan</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Huixquilucan</city>
        <state>Estado De Mexico</state>
        <zip>52763</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toluca</city>
        <state>Estado De Mexico</state>
        <zip>50180</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45150</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico</city>
        <state>Queretaro</state>
        <zip>76200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Callao</city>
        <zip>CALLAO 2</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 29</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bialystok</city>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baia Mare</city>
        <zip>430031</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Timisoara, Timis</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saxonwold</city>
        <state>Gauteng</state>
        <zip>2199</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gijon</city>
        <zip>33394</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kungalv</city>
        <zip>442 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sundsvall</city>
        <zip>851 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vaxjo</city>
        <zip>351 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cardiff</city>
        <state>Glamorgan</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Middlesex</state>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS8 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essex</city>
        <zip>CO3 3NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 13, 2015</lastchanged_date>
  <firstreceived_date>August 29, 2008</firstreceived_date>
  <firstreceived_results_date>November 15, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1930 participants were enrolled, and 1522 were randomized to a treatment group; 1518 received at least 1 dose of dasatinib (761) or placebo (757).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
        </group>
        <group group_id="P2">
          <title>Dasatinib</title>
          <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="760">Randomized</participants>
                <participants group_id="P2" count="762">Randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="757"/>
                <participants group_id="P2" count="761"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43">Remained on study drug</participants>
                <participants group_id="P2" count="39">Remained on study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="717"/>
                <participants group_id="P2" count="723"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance/noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study drug toxicity</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event unrelated to study drug</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient requested to stop study drug</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Maximum clinical benefit</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not defined</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who were randomized to receive any treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
        </group>
        <group group_id="B2">
          <title>Dasatinib</title>
          <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="760"/>
                <measurement group_id="B2" value="762"/>
                <measurement group_id="B3" value="1522"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Younger than 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="263"/>
                <measurement group_id="B2" value="251"/>
                <measurement group_id="B3" value="514"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>65 to younger than 75 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="323"/>
                <measurement group_id="B2" value="333"/>
                <measurement group_id="B3" value="656"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>75 years or older</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="174"/>
                <measurement group_id="B2" value="178"/>
                <measurement group_id="B3" value="352"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="760"/>
                <measurement group_id="B2" value="762"/>
                <measurement group_id="B3" value="1522"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="56"/>
                <measurement group_id="B2" value="55"/>
                <measurement group_id="B3" value="111"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="57"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="645"/>
                <measurement group_id="B2" value="656"/>
                <measurement group_id="B3" value="1301"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Type of metastatic disease</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Bone disease only</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="286"/>
                <measurement group_id="B2" value="307"/>
                <measurement group_id="B3" value="593"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Visceral/nodal disease only</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="73"/>
                <measurement group_id="B2" value="80"/>
                <measurement group_id="B3" value="153"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Both bone and visceral/nodal disease</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="399"/>
                <measurement group_id="B2" value="373"/>
                <measurement group_id="B3" value="772"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No evidence of metastatic disease</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival: Time From Randomization to Date of Death</title>
        <description>Overall survival is defined as time in months from the randomization date to the date of death due to any cause (in the randomized population). If the patient did not die, survival was censored on the last date he or she was known to be alive.</description>
        <time_frame>From randomization to death or date of last contact (maximum reached: 45 months)</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants who were randomized to receive any treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="760"/>
                  <measurement group_id="O2" value="762"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survival: Time From Randomization to Date of Death</title>
            <description>Overall survival is defined as time in months from the randomization date to the date of death due to any cause (in the randomized population). If the patient did not die, survival was censored on the last date he or she was known to be alive.</description>
            <units>Months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21.2" lower_limit="20.0" upper_limit="23.4"/>
                  <measurement group_id="O2" value="21.5" lower_limit="20.3" upper_limit="22.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence intervals calculated using Brookmeyer and Crowley method. Analysis compared survival in arms by 2-sided, alpha=0.05 level, log-rank test, stratified by bisphosphonate intake (yes/no) and urinary N-telopeptide category (&lt;60 vs ≥60 nmol/mmol creatinine) as defined at randomization. Null hypothesis was that survival was equal in both arms. Power calculations indicated that ≥858 deaths would lead to ≥90% power at 5% level for rejecting null hypothesis, given a true hazard ratio of 0.8.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.9009</p_value>
            <p_value_desc>An interim analysis on survival was performed. Final P-value was adjusted using an alpha spending function.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Objective Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <description>Objective tumor response rate=the percentage of randomized participants with a best tumor response of partial (PR) or complete response (CR), within 42 days of end of dosing, divided by total number of patients who were evaluable (with at least 1 target lesion at baseline). By RECIST: CR=disappearance of clinical and radiologic evidence of target and nontarget lesions confirmed by another evaluation at least 6 weeks later. PR=a &gt;30% or greater decrease in the sum of longest diameter (LD) of target lesions in reference to the baseline sum LD confirmed by another evaluation at least 6 weeks later. Stable disease=neither sufficient increase to qualify for PD nor shrinkage to qualify for PR, and at least 8 weeks since start of study therapy. Progressive disease=a 20% or greater increase in sum of LD of all target lesions, taking as reference the smallest sum of LD at or following baseline, or unequivocal progression on existing nontarget lesions, or new lesions are present.</description>
        <time_frame>At baseline and every 12 weeks thereafter to end of treatment, at end of treatment, and at follow-up (within 42 days of end of dosing)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants with at least 1 target lesion at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="383"/>
                  <measurement group_id="O2" value="381"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With an Objective Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (RECIST)</title>
            <description>Objective tumor response rate=the percentage of randomized participants with a best tumor response of partial (PR) or complete response (CR), within 42 days of end of dosing, divided by total number of patients who were evaluable (with at least 1 target lesion at baseline). By RECIST: CR=disappearance of clinical and radiologic evidence of target and nontarget lesions confirmed by another evaluation at least 6 weeks later. PR=a &gt;30% or greater decrease in the sum of longest diameter (LD) of target lesions in reference to the baseline sum LD confirmed by another evaluation at least 6 weeks later. Stable disease=neither sufficient increase to qualify for PD nor shrinkage to qualify for PR, and at least 8 weeks since start of study therapy. Progressive disease=a 20% or greater increase in sum of LD of all target lesions, taking as reference the smallest sum of LD at or following baseline, or unequivocal progression on existing nontarget lesions, or new lesions are present.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31.85" lower_limit="27.21" upper_limit="36.78"/>
                  <measurement group_id="O2" value="30.45" lower_limit="25.86" upper_limit="35.34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Since superiority of the dasatinib treatment group was not demonstrated for Overall Survival, secondary endpoints were not tested. The odds ratio is presented for experimental to control group.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.935</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.688</ci_lower_limit>
            <ci_upper_limit>1.271</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Skeletal-related Event (SRE)</title>
        <description>Time to first SRE is defined as the time in months from the date of randomization to the date of first SRE (unless SRE occurred while the patient was undergoing subsequent cancer therapy). Participants with a first SRE while on subsequent cancer therapy, those who died without a reported SRE, and those who did not have an SRE were censored on the date of their last SRE assessment prior to start of subsequent cancer therapy, if any. Participants who had no SRE assessments were censored on the day they were randomized.</description>
        <time_frame>From day of randomization to date of first SRE or to last SRE assessment, if subsequent cancer therapy begun or no SRE (maximum reached: 42 months)</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants who were randomized to receive any treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="760"/>
                  <measurement group_id="O2" value="762"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to First Skeletal-related Event (SRE)</title>
            <description>Time to first SRE is defined as the time in months from the date of randomization to the date of first SRE (unless SRE occurred while the patient was undergoing subsequent cancer therapy). Participants with a first SRE while on subsequent cancer therapy, those who died without a reported SRE, and those who did not have an SRE were censored on the date of their last SRE assessment prior to start of subsequent cancer therapy, if any. Participants who had no SRE assessments were censored on the day they were randomized.</description>
            <units>Months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31.1" lower_limit="28.8">Not estimable, due to the low percentage of participants experiencing skeletal-related events</measurement>
                  <measurement group_id="O2" value="NA">Not estimable, due to the low percentage of participants experiencing skeletal-related events</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Since superiority of the dasatinib treatment group was not demonstrated for Overall Survival, secondary endpoints were not tested. The hazard ratio is presented for experimental to control group.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With A Reduction in Urinary N-telopeptide (uNTx) Level From Baseline</title>
        <description>The percentage of participants who had an on-study uNTx value confirmed (at least 3 weeks later) within normal limits (or ≥3 and &lt;60 nmol/mmol creatinine, if normal limits were missing) or an on-study uNTx level reduction from baseline of ≥35%, even when on-study uNTx value remained abnormal.</description>
        <time_frame>At baseline, prior to each docetaxel infusion (every 3 weeks) to end of treatment, at end of treatment, and at follow-up (within 14 days of end of dosing)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who entered the study with baseline urinary N-telopeptide values higher than the upper limit of normal (ULN), or ≥60 nmol/mmol creatinine, if ULN was missing</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="335"/>
                  <measurement group_id="O2" value="321"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With A Reduction in Urinary N-telopeptide (uNTx) Level From Baseline</title>
            <description>The percentage of participants who had an on-study uNTx value confirmed (at least 3 weeks later) within normal limits (or ≥3 and &lt;60 nmol/mmol creatinine, if normal limits were missing) or an on-study uNTx level reduction from baseline of ≥35%, even when on-study uNTx value remained abnormal.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60.60" lower_limit="55.14" upper_limit="65.86"/>
                  <measurement group_id="O2" value="66.04" lower_limit="60.58" upper_limit="71.21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Since superiority of the dasatinib treatment group was not demonstrated for Overall Survival, secondary endpoints were not tested. The odds ratio is presented for experimental to control group.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.280</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.930</ci_lower_limit>
            <ci_upper_limit>1.763</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Those who progressed or died while on subsequent cancer therapy and those who did not die or progress were censored at their last radiologic bone scan/imaging, skeletal related-event, or tumor assessment or at measurement of prostate specific antigen levels, whichever occurred last prior to start of subsequent cancer therapy ,if any. Participants with no assessments were censored on the day of randomization.</description>
        <time_frame>From day of randomization to disease progression or death (or to last clinical assessment, if subsequent cancer therapy started or no progression or death) (maximum reached: approximately 43 months)</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants who were randomized to receive any treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="760"/>
                  <measurement group_id="O2" value="762"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression-free Survival (PFS)</title>
            <description>PFS is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Those who progressed or died while on subsequent cancer therapy and those who did not die or progress were censored at their last radiologic bone scan/imaging, skeletal related-event, or tumor assessment or at measurement of prostate specific antigen levels, whichever occurred last prior to start of subsequent cancer therapy ,if any. Participants with no assessments were censored on the day of randomization.</description>
            <units>Months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11.1" lower_limit="10.8" upper_limit="11.7"/>
                  <measurement group_id="O2" value="11.8" lower_limit="11.1" upper_limit="13.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Since superiority of the dasatinib treatment group was not demonstrated for Overall Survival, secondary endpoints were not tested. The hazard ratio is presented for experimental to control group.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Prostate Specific Antigen (PSA) Progression</title>
        <description>PSA progression is defined as the time from randomization to the date of the first PSA level measurement that led to confirmed PSA progression, for participants who had not started subsequent cancer therapy. For participants who did not progress or who progressed on cancer therapy, PSA progression is defined as the time from randomization to the date of the last PSA level measurement before the start of cancer therapy, if any. Participants who had no on-study PSA level measurements were censored on the day they were randomized.</description>
        <time_frame>From randomization to date of first PSA measurement leading to confirmed PSA progression (or to last bone scan assessment, if no progression or if cancer therapy started) (maximum reached: 30 months)</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants who were randomized to receive any treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="760"/>
                  <measurement group_id="O2" value="762"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Prostate Specific Antigen (PSA) Progression</title>
            <description>PSA progression is defined as the time from randomization to the date of the first PSA level measurement that led to confirmed PSA progression, for participants who had not started subsequent cancer therapy. For participants who did not progress or who progressed on cancer therapy, PSA progression is defined as the time from randomization to the date of the last PSA level measurement before the start of cancer therapy, if any. Participants who had no on-study PSA level measurements were censored on the day they were randomized.</description>
            <units>Months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.9" lower_limit="6.5" upper_limit="7.4"/>
                  <measurement group_id="O2" value="7.2" lower_limit="6.6" upper_limit="7.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Since superiority of the dasatinib treatment group was not demonstrated for Overall Survival, secondary endpoints were not tested. The hazard ratio is presented for of experimental to control group.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Reduction in Pain Intensity From Baseline</title>
        <description>The percentage of participants with a reduction in pain intensity from baseline was defined as the number of participants who achieved a 30% or more decrease in pain intensity from baseline for at least 2 consecutive pain assessments (at least 14 days apart) within 14 days of end of dosing divided by the number of randomized participants who had a baseline pain intensity of at least 2. Pain intensity was assessed based on question 3 of the brief pain inventory questionnaire.</description>
        <time_frame>At baseline, prior to each docetaxel infusion (every 3 weeks), at end of treatment, and at follow-up (within 14 days of end of dosing)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants with a baseline pain intensity of 2 or greater</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="467"/>
                  <measurement group_id="O2" value="419"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With a Reduction in Pain Intensity From Baseline</title>
            <description>The percentage of participants with a reduction in pain intensity from baseline was defined as the number of participants who achieved a 30% or more decrease in pain intensity from baseline for at least 2 consecutive pain assessments (at least 14 days apart) within 14 days of end of dosing divided by the number of randomized participants who had a baseline pain intensity of at least 2. Pain intensity was assessed based on question 3 of the brief pain inventory questionnaire.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="71.52" lower_limit="67.19" upper_limit="75.57"/>
                  <measurement group_id="O2" value="66.59" lower_limit="61.85" upper_limit="71.09"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Since superiority of the dasatinib treatment group was not demonstrated for Overall Survival, secondary endpoints were not tested. The odds ratio is presented for of experimental to control group.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.791</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.594</ci_lower_limit>
            <ci_upper_limit>1.052</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation</title>
        <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=having certain, probable, possible, or missing relationship to study drug</description>
        <time_frame>Continuously throughout study to &gt;=30 days after last dose of study drug until resolution of drug-related toxicity, or when toxicity was deemed irreversible, whichever shorter.</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All participants who received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="757"/>
                  <measurement group_id="O2" value="761"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation</title>
            <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=having certain, probable, possible, or missing relationship to study drug</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>All deaths</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="461"/>
                  <measurement group_id="O2" value="451"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Deaths on or within 30 days of treatment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>All SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="317"/>
                  <measurement group_id="O2" value="376"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Drug-related SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="148"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AEs leading to discontinuation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="186"/>
                  <measurement group_id="O2" value="293"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Drug-related AEs leading to discontinuation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="143"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adverse Events (AEs) of Special Interest</title>
        <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. AEs of Special Interest=recognized events in other agents within this drug class or events for which safety data from nonclinical and clinical studies with dasatinib indicate that careful evaluation is warranted. AEs of Special Interest are identified by the medical and safety representatives of the sponsor based on MedDRA preferred terms or laboratory data. ANC=absolute neutrophil count.</description>
        <time_frame>Continuously throughout study to &gt;=30 days after last dose of study drug until resolution of drug-related toxicity, or when toxicity was deemed irreversible, whichever was shorter</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All participants who received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="757"/>
                  <measurement group_id="O2" value="761"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Adverse Events (AEs) of Special Interest</title>
            <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. AEs of Special Interest=recognized events in other agents within this drug class or events for which safety data from nonclinical and clinical studies with dasatinib indicate that careful evaluation is warranted. AEs of Special Interest are identified by the medical and safety representatives of the sponsor based on MedDRA preferred terms or laboratory data. ANC=absolute neutrophil count.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Myelosuppression: Hemoglobin (n=746, 739)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="712"/>
                  <measurement group_id="O2" value="720"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myelosuppression: White blood cells (n=746, 738)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                  <measurement group_id="O2" value="149"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myelosuppression: ANC (n=745, 737)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84"/>
                  <measurement group_id="O2" value="161"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myelosuppression: Platelets (n=746, 738)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypocalcemia (n=739, 719)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="308"/>
                  <measurement group_id="O2" value="377"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypophosphotemia (n=733, 720)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="189"/>
                  <measurement group_id="O2" value="257"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypmagnesemia (n=734, 721)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                  <measurement group_id="O2" value="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="426"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea/vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="268"/>
                  <measurement group_id="O2" value="323"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="330"/>
                  <measurement group_id="O2" value="338"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgias/arthralgias</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="170"/>
                  <measurement group_id="O2" value="142"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="115"/>
                  <measurement group_id="O2" value="147"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal tract bleeding</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Central nervous system bleeding</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Other hemorrhage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="120"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fluid retention: Superficial edema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="184"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fluid retention: Pleural effusion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="118"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fluid retention: Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                  <measurement group_id="O2" value="98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Abnormalities in Results of Clinical Laboratory Tests in Hematology</title>
        <description>Abnormalities were graded according to the Common Toxicity Criteria (CTC), version 3.0, of the National Cancer Institute. CTC are graded from 1 (least severe) to 4 (life threatening ). Grade 3 and 4 criteria are defined as follows: Absolute neutrophil count, Grade 3, neutrophils &lt;1.0-0.5*10^9/L; Grade 4, &lt;0.5*10^9/L. Hemoglobin, Grade 3, &lt;4.9-4.0 mmol/L; Grade 4, &lt;4.0 mmol/L. Platelets, Grade 3, &lt;50.0-25.0*10^9/L; Grade 4, &lt;25.0*10^9/L. Leukocytes, Grade 3, &lt;2.0-1.0*10^9/L; Grade 4, &lt;1.0*10^9/L.</description>
        <time_frame>At baseline, within 3 days prior to each infusion of docetaxel (each cycle) and at end of treatment. If docetaxel is discontinued, every other cycle.</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All participants who received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="757"/>
                  <measurement group_id="O2" value="761"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Abnormalities in Results of Clinical Laboratory Tests in Hematology</title>
            <description>Abnormalities were graded according to the Common Toxicity Criteria (CTC), version 3.0, of the National Cancer Institute. CTC are graded from 1 (least severe) to 4 (life threatening ). Grade 3 and 4 criteria are defined as follows: Absolute neutrophil count, Grade 3, neutrophils &lt;1.0-0.5*10^9/L; Grade 4, &lt;0.5*10^9/L. Hemoglobin, Grade 3, &lt;4.9-4.0 mmol/L; Grade 4, &lt;4.0 mmol/L. Platelets, Grade 3, &lt;50.0-25.0*10^9/L; Grade 4, &lt;25.0*10^9/L. Leukocytes, Grade 3, &lt;2.0-1.0*10^9/L; Grade 4, &lt;1.0*10^9/L.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Absolute neutrophil count (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84"/>
                  <measurement group_id="O2" value="161"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Absolute neutrophil count (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="712"/>
                  <measurement group_id="O2" value="720"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelets (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelets (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leukocytes (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                  <measurement group_id="O2" value="149"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leukocytes (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Abnormalities in Results of Clinical Laboratory Tests Assessing Liver Function, Renal Function, and Electrolytes</title>
        <description>ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal. Abnormalities were graded according to the Common Toxicity Criteria (CTC), version 3.0, of the National Cancer Institute. CTC are graded from 1 (least severe) to 4 (life threatening). ALP, ALT, and AST, Grade 3, &gt;5.0-20.0*ULN; Grade 4, &gt;20.0*ULN. Total bilirubin, Grade 3, &gt;3.0–10.0*ULN; Grade 4, &gt;10.0*ULN. Creatinine, Grade 3, &gt;3.0–6.0*ULN; Grade 4, &gt;6.0*ULN. Hypercalcemia(serum calcium, mmol/L), Grade 3, &gt;3.1-3.4; Grade 4, &gt;3.4. Hypocalcemia (serum calcium, mmol/L), Grade 3, &lt;1.75-1.5; Grade 4, &lt;1.5. Hyperkalemia(serum calcium, mmol/L), Grade 3, &gt;6.0-7.0; Grade 4, &gt;7.0. Hypokalemia(serum calcium, mmol/L), Grade 3, &lt;3.0-2.5; Grade 4, &lt;2.5. Hypernatremia (serum calcium, mmol/L), Grade 3, &gt;155-160; Grade 4, &gt;160. Hyponatremia (serum sodium, mmol/L), Grade 3, &lt;130-120; Grade 4, &lt;120. Phosphorus (serum sodium, mmol/L), Grade 3, &lt;0.6-0.3; Grade 4, &lt;0.3.</description>
        <time_frame>At baseline, within 3 days prior to each infusion of docetaxel (each cycle), to end of treatment. If docetaxel is discontinued, every other cycle.</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All participants who received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="757"/>
                  <measurement group_id="O2" value="761"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Abnormalities in Results of Clinical Laboratory Tests Assessing Liver Function, Renal Function, and Electrolytes</title>
            <description>ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal. Abnormalities were graded according to the Common Toxicity Criteria (CTC), version 3.0, of the National Cancer Institute. CTC are graded from 1 (least severe) to 4 (life threatening). ALP, ALT, and AST, Grade 3, &gt;5.0-20.0*ULN; Grade 4, &gt;20.0*ULN. Total bilirubin, Grade 3, &gt;3.0–10.0*ULN; Grade 4, &gt;10.0*ULN. Creatinine, Grade 3, &gt;3.0–6.0*ULN; Grade 4, &gt;6.0*ULN. Hypercalcemia(serum calcium, mmol/L), Grade 3, &gt;3.1-3.4; Grade 4, &gt;3.4. Hypocalcemia (serum calcium, mmol/L), Grade 3, &lt;1.75-1.5; Grade 4, &lt;1.5. Hyperkalemia(serum calcium, mmol/L), Grade 3, &gt;6.0-7.0; Grade 4, &gt;7.0. Hypokalemia(serum calcium, mmol/L), Grade 3, &lt;3.0-2.5; Grade 4, &lt;2.5. Hypernatremia (serum calcium, mmol/L), Grade 3, &gt;155-160; Grade 4, &gt;160. Hyponatremia (serum sodium, mmol/L), Grade 3, &lt;130-120; Grade 4, &lt;120. Phosphorus (serum sodium, mmol/L), Grade 3, &lt;0.6-0.3; Grade 4, &lt;0.3.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALP (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="447"/>
                  <measurement group_id="O2" value="375"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALP (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91"/>
                  <measurement group_id="O2" value="68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="186"/>
                  <measurement group_id="O2" value="256"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="266"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total bilirubin (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total bilirubin (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="153"/>
                  <measurement group_id="O2" value="184"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypercalcemia (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypercalcemia (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypocalcemia (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="308"/>
                  <measurement group_id="O2" value="377"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypocalcemia (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyperkalemia (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="164"/>
                  <measurement group_id="O2" value="152"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyperkalemia (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypokalemia (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                  <measurement group_id="O2" value="152"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypokalemia (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypernatremia (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                  <measurement group_id="O2" value="101"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypernatremia (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyponatremia (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="230"/>
                  <measurement group_id="O2" value="241"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyponatremia (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Phosporus (All grades)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="189"/>
                  <measurement group_id="O2" value="257"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Phosphorus (Grades 3 and 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Abnormal Results in Urinalysis</title>
        <description>Abnormal=positive, defined as the presence of &gt;=30 mg/dL of protein; a small, moderate, or large amount of blood; or &gt;0 g/dL glucose in urine. BL=baseline; neg=negative</description>
        <time_frame>At baseline, within 3 days prior to each infusion of docetaxel (each cycle), to end of treatment. If docetaxel is discontinued, every other cycle.</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All participants who received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="757"/>
                  <measurement group_id="O2" value="761"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Abnormal Results in Urinalysis</title>
            <description>Abnormal=positive, defined as the presence of &gt;=30 mg/dL of protein; a small, moderate, or large amount of blood; or &gt;0 g/dL glucose in urine. BL=baseline; neg=negative</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Protein, urine: postive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="246"/>
                  <measurement group_id="O2" value="336"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood, urine: positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="289"/>
                  <measurement group_id="O2" value="307"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose, urine: positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="179"/>
                  <measurement group_id="O2" value="154"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants by Maximal On-study Fridericia-corrected QTc Interval by Electrocardiogram</title>
        <time_frame>At baseline, approximately 12 weeks after starting treatment, and then whenever clinically indicated up to within 30 days of end of dosing</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All participants who received treatment. n=number evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="757"/>
                  <measurement group_id="O2" value="761"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants by Maximal On-study Fridericia-corrected QTc Interval by Electrocardiogram</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&lt;450 msecs (n=600, 548)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="550"/>
                  <measurement group_id="O2" value="497"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>450-500 msecs (n=600, 548)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;500 msecs (n=600, 548)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Changes From Baseline in Fridericia-corrected QTc Interval by Electrocardiogram</title>
        <time_frame>At baseline, approximately 12 weeks after starting treatment, and then whenever clinically indicated up to within 30 days of end of dosing</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All participants who received treatment. n=number evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="757"/>
                  <measurement group_id="O2" value="761"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Changes From Baseline in Fridericia-corrected QTc Interval by Electrocardiogram</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>0 to 30 msecs increase (n=591, 540)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="199"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;30 to 60 msecs increase (n=591, 540)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;60 msecs increase (n=591, 540)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Decrease (n=591, 540)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                  <measurement group_id="O2" value="268"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With and Without Pericardial Effusion at Baseline and On-study and With Left Ventricular Ejection Fraction (LVEF) &lt;40% and &gt;=40%On-study by Echocardiogram</title>
        <description>BL=baseline; OS=on-study</description>
        <time_frame>At baseline, approximately 12 weeks after start of treatment, and thereafter whenever clinically indicated</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All participants who were randomized to receive any treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib</title>
            <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="760"/>
                  <measurement group_id="O2" value="762"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With and Without Pericardial Effusion at Baseline and On-study and With Left Ventricular Ejection Fraction (LVEF) &lt;40% and &gt;=40%On-study by Echocardiogram</title>
            <description>BL=baseline; OS=on-study</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pericardial effusion at BL/absent OS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pericardial effusion at BL/present OS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pericardial effusion at BL/not reported OS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pericardial effusion absent at BL/ absent OS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="584"/>
                  <measurement group_id="O2" value="545"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pericardial effusion absent at BL/present OS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pericardial effusion absent at BL/not reported OS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="132"/>
                  <measurement group_id="O2" value="184"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pericardial not reported at BL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LVEF OS &lt;40%</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LVEF OS &gt;=40%</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="607"/>
                  <measurement group_id="O2" value="566"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LVEF not reported OS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="194"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dasatinib</title>
          <description>Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="376" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="317" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Oesophageal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Balanoposthitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gastroenteritis radiation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Venous injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Clostridium test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Bone marrow myelogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Eastern Cooperative Oncology Group performance status worsened</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypercreatinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Colorectal cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Adenosquamous cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Astrocytoma malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>IIIrd nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Central nervous system haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Haemoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Urogenital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Testicular mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pulmonary venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Peau d'orange</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="714" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="698" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="283" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="227" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="411" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="312" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="331" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="327" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="216" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="205" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="311" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="325" subjects_at_risk="757"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="761"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="757"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
